Details for Patent: 9,839,619
✉ Email this page to a colleague
Which drugs does patent 9,839,619 protect, and when does it expire?
Patent 9,839,619 protects ADZENYS XR-ODT and is included in one NDA.
This patent has two patent family members in two countries.
Summary for Patent: 9,839,619
| Title: | Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles |
| Abstract: | The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. |
| Inventor(s): | Tengler Mark, McMahen Russell |
| Assignee: | NEOS THERAPEUTICS, LP |
| Application Number: | US13844555 |
|
Patent Claim Types: see list of patent claims |
More… ↓ |
Drugs Protected by US Patent 9,839,619
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-001 | Jan 27, 2016 | RX | Yes | No | 9,839,619 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-002 | Jan 27, 2016 | RX | Yes | No | 9,839,619 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-003 | Jan 27, 2016 | RX | Yes | No | 9,839,619 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-004 | Jan 27, 2016 | RX | Yes | No | 9,839,619 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-005 | Jan 27, 2016 | RX | Yes | No | 9,839,619 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-006 | Jan 27, 2016 | RX | Yes | Yes | 9,839,619 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,839,619
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2726066 | ⤷ Subscribe | |||
| World Intellectual Property Organization (WIPO) | 2013003622 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
